SIXL - ETF AI Analysis
Top Page
ETC 6 Meridian Low Beta Equity ETF (SIXL)
Rating:70Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and in recent months, showing solid momentum.
Broad Sector Diversification
Holdings are spread across many sectors like utilities, consumer defensive, financials, health care, and real estate, which helps reduce the impact of weakness in any one area.
Top Holdings Showing Strong Gains
Several of the largest positions, especially in health care and related names, have posted strong year-to-date gains that support the fund’s overall returns.
Negative Factors
Higher-Than-Index Expense Ratio
The fund’s expense ratio is higher than many broad market index ETFs, which means more of the return is used to cover fees.
Heavy U.S.-Only Exposure
Almost all assets are invested in U.S. companies, offering little geographic diversification if the U.S. market faces a downturn.
Sector Tilts Toward Defensives
Large weights in utilities, consumer defensive, and real estate may limit upside if more growth-oriented sectors like technology lead the market.
SIXL vs. SPDR S&P 500 ETF (SPY)
AUM206.17M
RegionNorth America
Expense Ratio0.46%
Beta0.32
IssuerMeridian
Inception DateMay 11, 2020
Dividend Yield2.15%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,236
30 Day Avg. Volume5,609
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
45.39Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering241
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SIXL Summary
The ETC 6 Meridian Low Beta Equity ETF (SIXL) is a U.S. stock fund that aims to give you broad market exposure while focusing on companies that tend to move less than the overall market. It doesn’t track a single index, but it follows a “low volatility” theme and spreads investments across many sectors like utilities, consumer defensive, financials, and health care. Well-known holdings include CVS Health and DaVita. Someone might invest for steadier, long-term growth and diversification. A key risk is that the fund can still lose value and may lag the market in strong bull markets.
How much will it cost me?The ETC 6 Meridian Low Beta Equity ETF (Ticker: SIXL) has an expense ratio of 0.47%, meaning you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it is actively managed, focusing on selecting low beta stocks to reduce market volatility. This strategy requires more research and management compared to passively managed funds.
What would affect this ETF?The SIXL ETF, with its focus on low beta equities and strong exposure to sectors like Utilities, Consumer Defensive, and Health Care, could benefit from economic stability or increased demand for defensive stocks during market uncertainty. However, it may face challenges if interest rates rise, as sectors like Real Estate and Utilities are sensitive to borrowing costs, or if growth-oriented sectors like Technology underperform. Its U.S.-centric exposure also ties its performance closely to domestic economic conditions and regulatory changes.
SIXL Top 10 Holdings
SIXL is quietly powered by a mix of steady U.S. health care and financial names, with biotech players like TG Therapeutics and Protagonist Therapeutics doing much of the heavy lifting as their shares keep rising. Virtu Financial has also been a helpful engine, adding momentum from the financial side. On the flip side, Progyny has been more of a speed bump lately, with its performance lagging and losing some steam. Overall, the fund leans into defensive, lower-volatility sectors, giving it a calmer, domestically focused profile despite a few more volatile growth stories inside.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| TG Therapeutics | 0.78% | $1.60M | $8.26B | 83.87% | 65 Neutral | |
| CoreCivic | 0.75% | $1.54M | $3.34B | 66.72% | 73 Outperform | |
| The Chefs' Warehouse | 0.72% | $1.47M | $4.69B | 82.13% | 72 Outperform | |
| Virtu Financial | 0.67% | $1.37M | $10.30B | 58.37% | 64 Neutral | |
| Protagonist Therapeutics | 0.66% | $1.37M | $9.34B | 144.42% | 68 Neutral | |
| Haemonetics | 0.66% | $1.37M | $4.73B | 90.61% | 70 Outperform | |
| Halozyme | 0.65% | $1.33M | $11.96B | 44.02% | 73 Outperform | |
| John Wiley Sons Cl A | 0.63% | $1.30M | $2.73B | 32.36% | 69 Neutral | |
| Progyny | 0.60% | $1.23M | $1.99B | 9.84% | 79 Outperform | |
| Sensient Technologies | 0.58% | $1.20M | $5.75B | 19.09% | 63 Neutral |
SIXL Technical Analysis
Neutral
―
Price Trends
39.83
Negative
38.93
Positive
38.13
Positive
Market Momentum
0.02
Positive
47.91
Neutral
33.36
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SIXL, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 39.93, equal to the 50-day MA of 39.83, and equal to the 200-day MA of 38.13, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 47.91 is Neutral, neither overbought nor oversold. The STOCH value of 33.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SIXL.
SIXL Peer Comparison
Comparison Results
Performance Comparison
SIXL
ETC 6 Meridian Low Beta Equity ETF
39.78
3.51
9.68%
VFMF
Vanguard U.S. Multifactor ETF
―
―
―
BGDV
Bahl & Gaynor Dividend ETF
―
―
―
AVTM
Avantis Total Equity Markets ETF
―
―
―
ULTY
YieldMax Ultra Option Income Strategy ETF
―
―
―
SMRI
Bushido Capital US Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents